Salute e Benessere

Therapeutic Plasma Exchange Market is Anticipated to Reach USD 2.9 billion, at a…

Healthcare professionals and patients are becoming more aware of the benefits of therapeutic plasma exchange. Thus, physicians have become increasingly interested in TPE as a treatment option. Researchers and clinicians are exploring TPE's potential applications. Research is currently being conducted to determine whether therapeutic plasma exchange can also be useful in other conditions. Healthcare professionals and patients are becoming more aware of the benefits of therapeutic plasma…
PR Newswire
13/12/2023

Epigenetics Market Worth $4.3 Billion | MarketsandMarkets

Browse in-depth TOC on "Epigenetics Market" 367 - Tables 45 - Figures366 - Pages Browse in-depth TOC on "Epigenetics Market"367 - Tables45 - Figures 366 - Pages Epigenetics Market Scope: The kits & reagents segment is expected to have the dominant share of the epigenetics market in 2022. Based on technology, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents is...
PR Newswire
13/12/2023

Novozymes' updated financial calendar

Please read the full announcement in PDF Attachment 2023_61_Updated_financial_calendar
Nasdaq GlobeNewswire
13/12/2023

Molecular Loop Biosciences Receives $1.8 Million to Expand Multi-pathogen…

Globally, there currently is a disparity in laboratories' ability to participate in comprehensive pathogen surveillance. Limited access to advanced genomic technologies poses a significant obstacle, particularly in LMICs. Molecular Loop will utilize this grant to develop and evaluate a multiplex NGS assay for the genomic analysis of the causative agents of respiratory infections. Through strategic partnerships and innovative technology, Molecular Loop aims to overcome technical barriers of…
PR Newswire
13/12/2023

Wandercraft unveils a groundbreaking innovation, its self-stabilizing Personal…

Wandercraft unveils a groundbreaking innovation, its self-stabilizing Personal Exoskeleton, at an exclusive event in New YorkExclusive in-person and virtual event today (link below) will reveal a groundbreaking innovation in robotics engineering from Wandercraft ahead of product finalization and market launchOnce cleared, the Personal Exoskeleton could be the first and only self-stabilizing walk exoskeleton in the market for personal everyday use, helping impaired people...
Nasdaq GlobeNewswire
13/12/2023

Fortrea Convenes New Site Advisory Board

Fortrea's Site Advisory Board brings research leaders together to focus on evolving site, sponsor and patient relationships Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it convened last week the inaugural meeting of its Site Advisory Board, a collaboration between clinical research investigator sites (“sites”) and industry leaders to create a better clinical trial experience for sites, patients and clinical study sponsors...
Nasdaq GlobeNewswire
13/12/2023

Rising Awareness, Tech Advancements, and Chronic Diseases Push Advanced Wound…

Request Exclusive Sample Report: Advance Wound Care Market Strategic Insights https://www.futuremarketinsights.com/reports/sample/rep-gb-13947 Request Exclusive Sample Report: Advance Wound Care Market Strategic Insightshttps://www.futuremarketinsights.com/reports/sample/rep-gb-13947 With the rising prevalence of lifestyle-related conditions such as diabetes and hypertension, individuals are increasingly susceptible to developing chronic wounds. These wounds need specialized care...
PR Newswire
13/12/2023

Cardiac Diagnostic Catheters Market Size to Reach USD 5.6 billion, at a 7.0%…

Patients' specific needs and characteristics are taken into account when developing diagnostic procedures and treatment plans. A specialized catheter that provides personalized diagnostic information may be developed due to this trend Patients' specific needs and characteristics are taken into account when developing diagnostic procedures and treatment plans. A specialized catheter that provides personalized diagnostic information may be developed due to this trend Fluoroscopy, ultrasound,...
PR Newswire
13/12/2023

Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating…

You can download a copy of the poster HERE >> https://info.imagionbio.com/sabcs-2023-poster-request You can download a copy of the posterHERE >> https://info.imagionbio.com/sabcs-2023-poster-request IBI10103 Phase I Study Results The IBI10103 clinical trial was closed inOctober 2023and evaluated the potential of the world's first molecularly targeted MRI contrast agent, MSH2IA (MagSense® HER2 Imaging Agent), to enhance clinicians' ability to non-invasively and more...
PR Newswire
13/12/2023

Disposable Contact Lenses Market worth $14.93 Bn by 2031 - Exclusive Report by…

Disposable Contact Lenses Market Report Scope Disposable Contact Lenses Market Report Scope Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2272 Disposable contact lenses can reduce complications that more commonly result from contact lenses worn for a longer time. These lenses are comparatively more comfortable, safe, and a better choice for people with dry eyes or allergies. The rising cases of eye disorders, fast advancements in contact lens...
PR Newswire
13/12/2023

Next Generation Complement Therapeutics Market worth $23.04 Bn by 2031 -…

The complement system recreates a crucial role in innate immunity and maintaining tissue homeostasis, and it protects against infection and flags apoptotic cells and debris for disposal. This complement system also contributes to the pathogenesis of inflammatory and autoimmune diseases and has driven industries and research institutes to develop novel 'next-generation' therapeutic drugs targeting different proteins and functions of the complement system. The complement system recreates a...
PR Newswire
13/12/2023

Acesion Pharma announces Nature Medicine publication of clinical results in…

In the trial, patients with a current episode of AF lasting for seven days or less were randomized to receive an intravenous infusion of 3 or 5 mg/kg of AP30663 or placebo. The primary endpoint of the trial was cardioversion from AF to sinus rhythm within 90 min from the start of the intravenous infusion, analysed using Bayesian statistics. In the trial, patients with a current episode of AF lasting for seven days or less were randomized to receive an intravenous infusion of 3 or 5 mg/kg of...
PR Newswire
13/12/2023

SYNDEO Medical Named by Business Worldwide Magazine as one of 2023's Top 20 Most…

At the heart of every operating theatre lies a combination of essential tools and materials needed to save and improve lives. Everything from surgical gloves to gowns, scalpels and intricate medical devices are brought together for every specific surgery, and for decades these were all conveniently provided in customised, sterile packs. This tailor-made approach worked for medical teams, and it's what they came to expect, but over the past five to seven years custom packs have become virtually…
PR Newswire
13/12/2023

Biocomposites exceeds revenue expectations and takes a big step forward in its…

2023 was a new record for the number of patients benefiting from a Biocomposites product as part of their treatment plan. This was a result of over 30% growth in demand for our products in China, India, UK, Europe and across the Americas - driven by product performance as well as a broadening of adoption beyond the traditional specialty of orthopaedics into new areas such as spine, foot and ankle, and podiatry. 2023 was a new record for the number of patients benefiting from a Biocomposites...
PR Newswire
13/12/2023

Engimmune Therapeutics strikes 'fast-forward' micro-fluidics collaboration with…

Engimmune's platform technologies – which comprise genome editing, deep sequencing, functional screening, and AI – provide a head start in the hunt for suitable soluble TCR candidates. Engimmune's platform technologies – which comprise genome editing, deep sequencing, functional screening, and AI – provide a head start in the hunt for suitable soluble TCR candidates. CSEM's expertise in microtechnologies and droplet microfluidics will enable Engimmune to accelerate clinical candidate...
PR Newswire
13/12/2023

Hansa Biopharma Nomination Committee formed

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee. The function of the Nomination Committee is to prepare and submit...
PR Newswire
13/12/2023

IBA, CMI and Life Molecular Imaging announce Japanese approval for the…

Louvain-la-Neuve, Belgium, 13 December, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the Japanese Ministry of Health has approved the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq ®(florbetaben 18F). Amyloid-PET imaging using agents like Neuraceq ®is used in the diagnosis of Alzheimer's disease and other forms of cognitive impairment...
Nasdaq GlobeNewswire
13/12/2023

Pharming Group announces development plans for leniolisib for additional primary…

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for2Q 2024Leiden, The Netherlands, December 13, 2023:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS)...
Nasdaq GlobeNewswire
13/12/2023

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

"This is a great Christmas present! Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment. This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic. "This is a great Christmas present! Alzheimer's disease patients inJapanwill now have access to the first disease modifying treatment. This gives hope for the large aging population inJapanwith a great need…
PR Newswire
13/12/2023

Camping Furniture Market Booming: Millennials' Travel Craze and Exploration…

Camping Furniture Industry Insights, 2024-2034: Camping Furniture Industry Insights, 2024-2034: Request Exclusive Sample Report: Campaign Furniture Market Strategic Insights:https://www.futuremarketinsights.com/reports/sample/rep-gb-18596 The global camping furniture market is primarily driven by the rising participation in camping and outdoor recreational activities, particularly among millennials. Such a trend reflects a growing interest in experiencing the great outdoors and...
PR Newswire
12/12/2023

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive…

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report Discover which therapies are expected to grab the major CIDP market share @Chronic Inflammatory Demyelinating Polyneuropathy Market Report Chronic Inflammatory Demyelinating Polyneuropathy Overview Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder that causes...
PR Newswire
12/12/2023

Innocan Pharma Announces Expert Team for LPT CBD Application to United States…

Dr. Robert B. Raffa, PhD, is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy. He was a Research Fellow and a Team Co-Leader for analgesics drug discovery at Johnson & Johnson Inc., where he was pivotal in the elucidation of the mechanism of action and development of the analgesic drug tramadol (Ultram™). He is a Co-Founder and the Vice President of Biology of CaRafe Drug Innovation LLC, a Co-Founder and member…
PR Newswire
12/12/2023

Update on the merger approval process for the combination of Novozymes and Chr…

December 12, 2023 Please see attachment.Contact informationInvestor RelationsDisa Tuominen +45 6038 5826dkditu@chr-hansen.comPress RelationsSanne Seyer-Hansen +45 6038 6207dksash@chr-hansen.comAttachment 2023_Conditional competition clearance from the European Commission obtained
Nasdaq GlobeNewswire
12/12/2023

Update on the merger approval process for the combination of Novozymes and Chr…

Please read the full announcement in PDF Attachment 2023_Conditional_competition_clearance_from_the_EC
Nasdaq GlobeNewswire
12/12/2023
Altri  Comunicati